Serum LDH: A marker of disease activity and its response to therapy in idiopathic pulmonary fibrosis

Netherlands Journal of Medicine

Volumn 48, Issue 6, 1996, Pages 220-222

  Van Krugten, M ^a   Cobben, N A M ^a   Lamers, R J S ^a   Van Dieijen Visser, M P ^a   Wagenaar, Sj Sc ^a   Wouters, E F M ^a   Drent, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cryptogenic fibrosing alveolitis; Idiopathic pulmonary fibrosis (IPF); Lactate dehydrogenase (LDH)

Indexed keywords

BIOCHEMICAL MARKER; CYCLOPHOSPHAMIDE; LACTATE DEHYDROGENASE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; DIAGNOSIS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG THERAPY; ENZYME ACTIVITY; FEMALE; HUMAN; IDIOPATHIC DISEASE; LUNG FIBROSIS;

EID: 0030012949     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/0300-2977(95)00074-7     Document Type: Article

References (14)

1. Dunnill MS. Pulmonary fibrosis. Histopathology 1990;16: 321-329.
2. Drent M, van Nierop NAMF, Gerritsen FA, Wouters EFM, Mulder PGH. A computer program using BALF-analysis results as a diagnostic tool in interstitial lung diseases. Am J Respir Crit Care Med 1996;153:736-741.
3. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage fluid and venous blood constituents in idiopathic pulmonary fibrosis and selected comparison groups. Am Rev Respir Dis 1990:S188-S192.
4. Winterbauer RH, Hamman SSP, Hallman KO, et al. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1987;65:661-672.
5. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in cryptogenic fibrosing alveolitis. Thorax 1989;44:280-288.
6. Turner-Warwick M, Haslam PL. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987;135:26-34.
7. van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:1950-1957.
8. Dayton CS, Schwartz DA, Helmers RA, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy - implications for further studies. Chest 1993;103:69-73.
9. Matusiewicz SP, Williamson IJ, Sime PJ, et al. Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? Eur Respir J 1993;6:1282-1286.
10. DeRemee RA. Serum lactic dehydrogenase activity in diffuse interstitial pneumonitis. J Am Med Assoc 1986;204:1193-1195.
11. 3) in experimentally induced immunologic lung injury. Am J Pathol 1971;64:575-584.
12. Schultze AE, Gunaga KP, Wagner JG, Hoorn CM, Moorehead WR, Roth RA. Lactate dehydrogenase activity and isoenzyme pattern in tissues and bronchoalveolar lavage fluid from rats treated with monocrotaline pyrrole. Toxicol. Appl. Pharmacol., 1994;126:301-310.
13. Lott JA, Nemensanszky E. Lactate dehydrogenase (LD). In: Lott JA, Wolf PL, eds. Clinical enzymology, a case-oriented approach. 1987;213-244.
14. Panus PC, Matalon S, Freeman BA. Responses of type II pneumocyte antioxidant enzymes to normoxic and hyperoxic culture. In Vitro Cell Dev Biol 1989; 25:821-829.